Janus kinase (JAK) inhibitors have shown efficacy in treating moderate-to-severe atopic dermatitis in clinical trials, but concerns remain regarding long-term safety. Therefore, this systematic review and meta-analysis aimed to evaluate adverse events associated with JAK inhibitors using real-world data. We searched PubMed, Scopus, and Web of Science and included studies reporting adverse events in real-world settings. The pooled prevalence of adverse events was estimated using a random-effects model. Statistical heterogeneity was evaluated using the I² statistic. A total of 35 studies were analyzed. The most common adverse event was elevated creatine phosphokinase (15%), followed by acne (14%) and increased lipid levels (13%). Regarding infections, 6% had herpes simplex, 2% herpes zoster, and 5% respiratory infections. These findings highlight the importance of monitoring laboratory parameters and clinical symptoms for patient safety. (PROSPERO Registration: CRD42024569258)